48
Participants
Start Date
March 4, 2022
Primary Completion Date
July 2, 2024
Study Completion Date
August 22, 2025
CC-93538
Specified dose on specified days
Placebo
Specified dose on specified days
Local Institution - 024, Gifu
Local Institution - 022, Himeji-shi
Local Institution - 009, Nishinomiya
Local Institution - 0025, Tsu
Local Institution - 025, Tsu
Local Institution - 023, Sendai
Local Institution - 007, Bunkyo-ku
Local Institution - 001, Setagaya-ku
Local Institution - 010, Akita
Local Institution - 017, Hirosaki
Local Institution - 015, Hiroshima
Local Institution - 018, Kagoshima
Local Institution - 020, Kitakyushu
Local Institution - 004, Kobe
Local Institution - 011, Maebashi
Local Institution - 013, Nagaoka
Local Institution - 016, Nagasaki
Local Institution - 006, Nagoya
Local Institution - 021, Nagoya
Local Institution - 008, Niigata
Local Institution - 002, Osaka
Local Institution - 012, Ōgaki
Local Institution - 005, Shibukawa
Local Institution - 019, Tokyo
Local Institution - 003, Yamagata
Lead Sponsor
Celgene
INDUSTRY